AWE18Пептидомиметик AWE18
An experimental cyclic peptidomimetic containing alanine, glutamate and tryptophan. Researchers studied its effects on hematopoiesis, the formation of blood cells.
What the studies found
Animal research · 2016
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Study of multiple preparations
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
Study notes · methods, sources and limitations
Participants or model Intact mice, donor marrow and irradiated recipient-mouse colony assays
Important limitations
- AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported. Related publications may share experiments; source count is not independent-study count.
ChemMedChem · Publication record
Review of earlier studies · 2023
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Study of multiple preparations
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
Study notes · methods, sources and limitations
Participants or model Source-specific experimental population
Important limitations
- Independent replication and full risk-of-bias appraisal remain unresolved. No personalized treatment or safety conclusion follows from this record.
International Journal of Molecular Sciences 24(17):13534 · Publication record
About AWE18
Research background
Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.
Conference sources and research collaborators ↗
- Compound class
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
See preparation-specific records; human benefit not established here
Study methods
Source-specific designs and limitations below
Independent replication
Related reports are not automatically independent evidence
Source access
Linked publications; access and review scope shown per record
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Experiment described in a patent · 2013
Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Study notes and original source
Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Vladislav I. Deigin · EP2046778B1 · patent family 38996830
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Results and tables
Reported patent results
Reported findings
One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.
Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
Population or model Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Protein-antigen response | A tested cyclic compound reportedly increased antibody titers by 74% | A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result |
| Oral activity comparison | Some cyclic analogues retained oral analgesic activity where comparator peptides did not | Different neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective |
Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
- Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Animal research · 2016
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
Study notes and original source
Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.
Preparation-specific research; no equivalence inferred
Deigin V, Ksenofontova O, Khrushchev A, Yatskin O, Goryacheva A, Ivanov V. · ChemMedChem
Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.
- Population / setting
- Intact mice, donor marrow and irradiated recipient-mouse colony assays
- Source reviewed
- Full primary text checked: compound 3 is the alanine cyclic scaffold later discussed as AWE18 in the 2023 platform review. Experimental comparisons concern mice and irradiated marrow; supporting raw data not independently reanalyzed.
Study limitations
- AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Review of earlier studies · 2023
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
Study notes and original source
Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides
Defined synthetic peptide / analogue
Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534
Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.
- Population / setting
- Source-specific experimental population
- Source reviewed
- Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Study limitations
- Independent replication and full risk-of-bias appraisal remain unresolved.
- No personalized treatment or safety conclusion follows from this record.
Reviewed 2026-10-02.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗